Angeles Investment Advisors LLC Acquires 376 Shares of Edwards Lifesciences Co. (NYSE:EW)

Angeles Investment Advisors LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,739 shares of the medical research company’s stock after purchasing an additional 376 shares during the period. Angeles Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $438,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $28,000. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences during the 2nd quarter valued at about $29,000. Riverview Trust Co purchased a new position in Edwards Lifesciences in the first quarter worth about $34,000. Finally, Pingora Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $38,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,250 shares of company stock worth $1,218,138. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. UBS Group reduced their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft reduced their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, July 25th. Barclays lowered their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Truist Financial reduced their price objective on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a report on Friday. Finally, Royal Bank of Canada decreased their target price on Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, July 25th. Fifteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $80.29.

Edwards Lifesciences Stock Up 0.6 %

EW stock opened at $68.52 on Monday. The business’s 50-day moving average price is $72.39 and its 200-day moving average price is $83.45. The stock has a market cap of $41.28 billion, a P/E ratio of 29.53, a PEG ratio of 2.85 and a beta of 1.13. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.66 earnings per share. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.